JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanton, H. C.
Right arrow Articles by Parmenter, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanton, H. C.
Right arrow Articles by Parmenter, K.
Journal of Pharmacology And Experimental Therapeutics, Vol. 149, Issue 2, 174-182, 1965
Copyright © 1965 by American Society for Pharmacology and Experimental Therapeutics


CARDIOVASCULAR PHARMACOLOGY OF TWO NEW beta-ADRENERGIC RECEPTOR ANTAGONISTS

H. C. Stanton 1, T. Kirchgessner 1, and K. Parmenter 1

1 Mead Johnson Research Center, Evansville, Indiana

The beta-adrenergic receptor blocking activities of three agents, MJ 1999 [4-(2-isopropylamino-1-hydroxyethyl)methanesulfonanilide hydrochloride], MJ 1998 [4-(2-methylamino-1-hydroxypropyl) methanesulfonanilide hydrochloride] and pronethalol were compared using a number of cardiovascular procedures. The orders of beta- receptor blocking potency based upon the capacity of the compounds to block the positive inotropic and/or chronotropic actions of isoproterenol on the heart were as follows: isolated perfused cat heart, MJ 1999 = pronethalol > MJ 1998; anesthetized dog (i. v.), MJ 1999 > pronethalol > MJ 1998. In addition, the three agents antagonized the positive inotropic actions on the heart elicited by electrical stimulation of the cardioaccelerator nerve, epinephrine and norepinephrine.

Intrinsic cardiac stimulation was observed with low doses of pronethalol and with large doses of MJ 1998. No stimulating activities were observed with MJ 1999; a mild decrease in cardiac function, indicated by a slowed rate and decreased contractile force, occurred with larger doses.

MJ 1999 did not alter arterial blood pressure, femoral arteriolar resistance, total peripheral resistance or coronary arteriolar resistance. All of these parameters were reduced by pronethalol. MJ 1998 acted as a vasoconstrictor in large doses and increased total peripheral resistance, arterial blood pressure and pulmonary arterial resistance when administered by intravenous infusion to the dog. MJ 1998 increased femoral arteriolar resistance but not coronary arteriolar resistance when administered intraarterially.

MJ 1999, but not MJ 1998, partially protected guinea pigs from ouabain cardiotoxicity. In addition, MJ 1999 reduced the atrial rate of animals with atrial flutter induced by aconitine or injury stimulation.

The order of decreasing cardiovascular toxicity based upon infusion studies in anesthetized dogs was: pronethalol > MJ 1999 > MJ 1998.

Accepted on March 15, 1965







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics.